Clinton Musil
Directeur Général chez Skyhawk Therapeutics, Inc.
Profil
Clinton Musil is currently the Chief Executive Officer at Skyhawk Therapeutics, Inc. He previously held positions as Vice President in the Healthcare Investment Banking Group at Wells Fargo & Co. and Deutsche Bank AG.
He also served as the Chief Business Officer at Personalis, Inc., Principal at Needham & Co. LLC, and Vice President at Essex Woodlands Management, Inc. Additionally, he was the Vice President of Corporate Development at ARMO BioSciences, Inc. from 2017 to 2018.
In 2020, he became the Chief Financial Officer at Catalyst Biosciences, Inc. before transitioning to the role of Chief Financial Officer at Skyhawk Therapeutics, Inc. in 2021.
Mr. Musil obtained his undergraduate degree from the University of Arizona and holds an MBA from Harvard Business School.
Postes actifs de Clinton Musil
| Sociétés | Poste | Début |
|---|---|---|
Skyhawk Therapeutics, Inc.
 Skyhawk Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Skyhawk Therapeutics, Inc. discovers and develops small molecule therapeutics for RNA-based disease. It is developing drug candidates for cancer, neurological disease, and rare disease. The company was founded by William M. Hanley III and Kathleen McCarthy and is headquartered in Waltham, MA. | Directeur Général | 11/06/2024 |
Anciens postes connus de Clinton Musil
| Sociétés | Poste | Fin |
|---|---|---|
Skyhawk Therapeutics, Inc.
Skyhawk Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Skyhawk Therapeutics, Inc. discovers and develops small molecule therapeutics for RNA-based disease. It is developing drug candidates for cancer, neurological disease, and rare disease. The company was founded by William M. Hanley III and Kathleen McCarthy and is headquartered in Waltham, MA. | Directeur Financier/CFO | 01/02/2024 |
| CATALYST BIOSCIENCES | Directeur Financier/CFO | 29/10/2021 |
| ARMO BIOSCIENCES INC | Corporate Officer/Principal | 01/07/2018 |
| DEUTSCHE BANK AG | Corporate Officer/Principal | 01/03/2017 |
| WELLS FARGO & COMPANY | Corporate Officer/Principal | 01/07/2014 |
Formation de Clinton Musil
| University of Arizona | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| PERSONALIS, INC. | Health Services |
| DEUTSCHE BANK AG | Finance |
| WELLS FARGO & COMPANY | Finance |
| Entreprise privées | 5 |
|---|---|
Essex Woodlands Management, Inc.
 Essex Woodlands Management, Inc. Investment ManagersFinance Essex Woodlands Management, Inc. (EW Healthcare Partners) is a private equity firm founded in 1985 by Jim L. Currie and Martin P. Sutter. The firm is headquartered in Houston, Texas. | Finance |
Needham & Co. LLC
 Needham & Co. LLC Investment Banks/BrokersFinance Needham & Co. LLC (Needham) is a registered investment advisor and broker/dealer headquartered in New York City. The firm was founded in 1985 and is a wholly-owned indirect subsidiary of The Needham Group, Inc. Needham provides corporate and institutional clients with high quality research, corporate access, capital markets and trading execution services in both the public and private markets, with an emphasis on growth companies. | Finance |
ARMO BioSciences, Inc.
 ARMO BioSciences, Inc. Pharmaceuticals: MajorHealth Technology ARMO BioSciences, Inc. develops immunotherapy for the treatment of cancer, cardiovascular diseases, fibrosis, and inflammation. Its lead product candidate is AM0010 (pegilodecaki). The company was founded by Peter Van Vlasselaer, Martin Oft, and John B. Mumm on June 23, 2010 and is headquartered in Redwood, CA. | Health Technology |
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
Skyhawk Therapeutics, Inc.
Skyhawk Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Skyhawk Therapeutics, Inc. discovers and develops small molecule therapeutics for RNA-based disease. It is developing drug candidates for cancer, neurological disease, and rare disease. The company was founded by William M. Hanley III and Kathleen McCarthy and is headquartered in Waltham, MA. | Health Technology |
